Fedratinib,
N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino) pyrimidin-4-ylamino)benzenesulfonamide,
SAR302503,
TG101348,
936091-26-8,
Fedratinib,
Tg-101348,
TG101348,
SAR302503,
TG 101348,
SAR-302503,
UNII-6L1XP550I6,
Fedratinib (SAR302503, TG101348),
TG101348 (SAR302503),
SAR 302503,
CHEMBL1287853,
C27H36N6O3S,
6L1XP550I6,
N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide,
N-(tert-butyl)-3-((5-methyl-2-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)pyrimidin-4-yl)amino)benzenesulfonamide,
N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidin-4-ylamino)benzenesulfonamide,
N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzenesulfonamide,
Fedratinib [USAN:INN],
TG101348 HCl,
2TA,
Fedratinib (USAN/INN),
Fedratinib TG101348,
cc-67,
TG101348(Fedratinib),
MLS006011155,
SCHEMBL263741,
GTPL5716,
CHEBI:91408,
AOB2041,
DTXSID90239483,
EX-A170,
SYN1104,
HMS3656L19,
BCP02300,
ABP000705,
BDBM50332294,
MFCD12922515,
RS0112,
s2736,
ZINC19862646,
AKOS015842621,
AN-4247,
CS-0052,
DB12500,
EX-5961,
KIN0000251,
SB14604,
Fedratinib-SAR302503-TG101348,
NCGC00244252-01,
NCGC00244252-07,
AC-30260,
AK-50248,
AS-16248,
BC644857,
Benzenesulfonamide, N-(1,1-dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)-,
DA-40258,
DA-45538,
HY-10409,
N-Tert-butyl-3-(5-methyl-2-(4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino)-pyrimidin-4-ylamino)-benzenesulfonamide,
N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide,
SC-86405,
SMR004702929,
AB1008513,
FT-0705969,
FT-0763396,
FT-0766818,
SW218187-2,
Y0268,
A25534,
D10630,
W-5547,
SAR302503 (TG-101348),
TG101348/TG-101348/,
091D268,
J-523769,
BRD-K12502280-001-01-5,
N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyr,
936091-26-8 pound not TG101348 pound not TG 101348,
3-methyl-5-(2-morpholinoethyl)-6,7-dehydro-1H-pyrrolo[3,2-c]pyridine-4(5H)-one,
945381-69-1,
Fedratinib|||N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-benzenesulfonamide,
n-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino,
N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzene-1-sulfonamide,
null,
JAK inhibitors,
Fedratinib [USAN],
D0G8BM,
A4136,
A11082,
C528327,
TG-101348, 98% - 100MG 100mg,
1374744-69-0,
N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino) pyrimidin-4-ylamino)benzenesulfonamide,
N-Tert-butyl-3-(5-methyl-2-(4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino)-pyrimidin-4-ylamino) benzenesulfonamide,
N-Tert-butyl-3-(5-methyl-2-(4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino)-pyrimidin-4-ylamino)benzenesulfonamide,
N-tert-butyl-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide,